LobbyingThe Livingston Group on Behalf of Innovative Vaccine Technologies lobbying by quarter
The Livingston Group on Behalf of Innovative Vaccine Technologies's latest lobbying report covers Q3 2026, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Medical/Disease Research/Clinical Labs.
The Livingston Group on Behalf of Innovative Vaccine Technologies
- Latest quarter
- $0
- Q3 2026 · 1 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $30K | 1 |
| Q1 2023 | $30K | 1 |
| Q2 2023 | $30K | 1 |
| Q3 2023 | $30K | 1 |
| Q4 2023 | $30K | 1 |
| Q1 2024 | $20K | 1 |
| Q2 2024 | $20K | 1 |
| Q3 2024 | $20K | 1 |
| Q4 2024 | $20K | 1 |
| Q1 2025 | $20K | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $0 | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 1 |
By issue
- Budget and appropriations$125K · 16 reports
- Medical research and clinical labs$125K · 16 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES16 reports
- SENATE15 reports
- Defense, Dept of (DOD)6 reports
Firms it paid
| Firm | ||
|---|---|---|
| Magill Associates | $250K | 16 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JOHN PIERSON MAGILL | COS to Rep. Wally Herger | Q3 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 10/01for Q3 | Magill Associates | Under $5,000 |
| 07/07for Q2 | Magill Associates | Under $5,000 |
| 04/01for Q1 | Magill Associates | Under $5,000 |
| 01/06for Q4 2025 | Magill Associates | Under $5,000 |
| 25/10/02for Q3 2025 | Magill Associates | Under $5,000 |
| 25/07/09for Q2 2025 | Magill Associates | Under $5,000 |
| 25/04/01for Q1 2025 | Magill Associates | $20K |
| 25/01/02for Q4 2024 | Magill Associates | $20K |
| 24/10/02for Q3 2024 | Magill Associates | $20K |
| 24/07/02for Q2 2024 | Magill Associates | $20K |
| 24/04/02for Q1 2024 | Magill Associates | $20K |
| 24/01/04for Q4 2023 | Magill Associates | $30K |
| 23/10/05for Q3 2023 | Magill Associates | $30K |
| 23/07/05for Q2 2023 | Magill Associates | $30K |
| 23/04/03for Q1 2023 | Magill Associates | $30K |
| 23/01/10for Q4 2022 | Magill Associates | $30K |